SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: ted who wrote (562)2/5/1999 12:58:00 PM
From: Charles Tutt  Read Replies (1) | Respond to of 1298
 
Could CEGE muster enough resources ($$$ and management time) to sue an infringer?



To: ted who wrote (562)2/5/1999 9:45:00 PM
From: JMarcus  Read Replies (1) | Respond to of 1298
 
ted,

TGEN's 10K states that they license NIH's patent for aav in CF. I haven't a clue as to whether CEGE would claim priority over NIH's patent. Clearly, however, TGEN doesn't have any prospect of developing any more aav drugs unless it obtains additional licenses from someone.

Marc


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News